Severe pulmonary complications after bortezomib treatment in multiple myeloma.

摘要

Multiple myeloma (MM) remains an incurable disease, and therefore new therapies are needed to improve the outcome of these patients. Bortezomib, a promising agent for MM, exhibits significant anti-myeloma activity. With the recent extensive use of bortezomib in MM patients, it has revealed some complications whose pathogenesis remains often mistiness. Most side effects attributable to bortezomib therapy are only mild to moderate and generally manageable. The incidences of serious side effects have been reportedly so far less than 5% [1-3]. Notably, severe pulmonary complications after bortezomib use have been reported rarely. Especially, this kind of complications associated with poor prognosis [4-6].